Utama › Kanser Prostat › Pennsylvania › Philadelphia
Kajian klinikal Kanser Prostat di Philadelphia, PA
44 kajian untuk Kanser Prostat sedang mencari peserta di lokasi dalam dan sekitar Philadelphia (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Mengambil pesertaFasa 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13 mi jauh
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mi jauh
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Mengambil pesertaFasa 1
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
DESTINY-PANTUMOUR04
Mengambil pesertaKajian pemerhatian
- Research Site, Philadelphia
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Mengambil pesertaFasa 3
- Fox Chase Cancer Center ( Site 0076), Philadelphia
- MidLantic urology ( Site 0022), Bala-Cynwyd · 5 mi jauh
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Mengambil pesertaFasa 3
- MidLantic urology, Bala-Cynwyd · 5 mi jauh
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Mengambil pesertaFasa 2/3
- Fox Chase Cancer Center, Philadelphia
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Mengambil pesertaFasa 2
- Philadelphia MultiService Center, Philadelphia, PA, Philadelphia
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Mengambil pesertaFasa 3
- Perelman Center for Advanced Medicine ( Site 0067), Philadelphia
- Abramson Cancer Center - Penn Medicine ( Site 0079), Philadelphia
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Mengambil pesertaFasa 1/2
- GSK Investigational Site, Philadelphia
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Mengambil pesertaFasa 1
- Thomas Jefferson University, Philadelphia
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Mengambil peserta
- MidLantic Urology, Bala-Cynwyd · 5 mi jauh
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Mengambil pesertaFasa 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi jauh
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi jauh
A Study of Tarlatamab for People With Prostate Cancer
Mengambil pesertaFasa 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Mengambil pesertaFasa 2
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaFasa 1
- Thomas Jefferson University, Philadelphia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Mengambil pesertaFasa 3
- Penn Presbyterian Medical Center, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Mengambil pesertaFasa 1
- Thomas Jefferson University Honickman Center, Philadelphia
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Mengambil pesertaFasa 1
- Thomas Jefferson University, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Investigative Site #109, Philadelphia
PSMA PET Combined With MRI for the Detection of PCa
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
- MidLantic Urology, Philadelphia
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Mengambil pesertaFasa 3
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi jauh
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi jauh
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Mengambil pesertaFasa 1
- MidLantic Urology, Bala-Cynwyd · 5 mi jauh
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Mengambil pesertaFasa 1
- Thomas Jefferson University, Philadelphia
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Mengambil pesertaFasa 1/2
- Thomas Jefferson University Hospital, Philadelphia
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Mengambil pesertaFasa 2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia
TERPS Trial for de Novo Oligometastic Prostate Cancer
Mengambil pesertaFasa 2
- Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Mengambil pesertaKajian pemerhatian
- Fox Chase Cancer Center - Temple Health, Philadelphia
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Mengambil peserta
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Mengambil pesertaFasa 2/3
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Mengambil pesertaFasa 1/2
- Research Site, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Mengambil pesertaFasa 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Hypofractionated WPPT With HDR Boost
Mengambil pesertaFasa 2
- University of Pennsylvania, Philadelphia
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Mengambil pesertaFasa 1
- MidLantic Urology, Bala-Cynwyd · 5 mi jauh
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Mengambil pesertaFasa 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi jauh
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi jauh
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Mengambil pesertaFasa 4
- Albert Einstein Healthcare Network, Philadelphia
Prostate Tissue BioBank
Mengambil pesertaKajian pemerhatian
- University of Pennsylvania, Philadelphia
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
Mengambil peserta
- Fox Chase Cancer Center, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Philadelphia
Kajian Kanser Prostat di bandar lain
- New York City, NY103 kajian
- Houston, TX76 kajian
- Los Angeles, CA61 kajian
- Boston, MA59 kajian
- St. Louis, MO46 kajian
- Chicago, IL45 kajian
- San Francisco, CA45 kajian
- Baltimore, MD43 kajian
- Nashville, TN42 kajian
- Seattle, WA42 kajian
- Washington, DC38 kajian
- Dallas, TX36 kajian
Kajian lain di Philadelphia
- Kanser (semua jenis)59 kajian
- Kanser Payudara56 kajian
- Kanser Paru-paru Bukan Sel Kecil51 kajian
- Kanser Metastatik46 kajian
- Kanser Kolorektal44 kajian
- Kanser Ovari44 kajian
- Kanser Paru-paru36 kajian
- Leukemia Mieloid Akut34 kajian
- Kegagalan Jantung31 kajian
- Kanser Endometrium28 kajian
- Depresi26 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.